Tissue-Specific RNA Delivery Pipeline — PatSnap Eureka
Tissue-Specific RNA Delivery: Muscle, Cardiac, CNS & Lung Formulation Approaches
From DCA-siRNA conjugates achieving ~80% cardiac silencing to intrathecal mRNA for SMA, this intelligence report maps the patent and literature landscape for organ-targeted nucleic acid therapeutics across four critical tissue compartments.
Six Delivery Modalities Shaping Tissue-Targeted RNA Therapeutics
From clinically approved LNPs to emerging exosome engineering, each platform addresses distinct barriers to organ-selective nucleic acid delivery. Innovation is tracked across PatSnap's IP analytics platform.
Lipid Nanoparticles (LNPs)
The canonical LNP architecture—ionizable amine lipid, helper lipid, cholesterol, and PEGylated lipid—is the current state-of-the-art for systemic nucleic acid delivery. Liver is the default accumulation organ following IV administration. Endosomal escape via pH-sensitive ionizable lipid structural transitions is mechanistically highlighted as the key bottleneck for LNP efficacy at all tissue sites. Extrahepatic targeting for cardiovascular, neurological, and infectious indications is framed as the major next-generation challenge.
✅ Clinically Approved (patisiran, COVID-19 vaccines)Conjugate-Based Delivery (DCA-siRNA, GalNAc, PNA-Peptide)
Docosanoic acid (DCA) conjugation of siRNAs drives systemic delivery to skeletal and cardiac muscle with ~5% injected dose efficiency and sustained silencing >1 month with no cytokine induction at 100 mg/kg. A TfR1-targeted PNA-peptide antagomir inhibited miR-21 in cardiomyocytes and across heart, liver, kidney, lung, and spleen in vivo. GalNAc conjugation enables liver sinusoidal endothelial cell-specific delivery—clinically approved as inclisiran.
⚗️ DCA-siRNA: Preclinical | GalNAc: ApprovedPolymer-Based Nanocarriers (PEI, PAMAM, Poly(ester amine))
PEI nanoparticles functionalized with a muscle-specific RNA aptamer deliver ASOs specifically to muscle cells via coaxial electrospraying, with confocal microscopy confirming tissue-selective transfection. An anionic mRNA/PEI/γ-PGA complex improves safety over standard cationic PEI. TRON's active EP patent claims polyalkyleneimine polyplex formulations for intramuscular delivery of self-replicating RNA.
🔬 Predominantly PreclinicalExosome / Extracellular Vesicle (EV) Delivery
Plasmid-driven endogenous exosome biogenesis (Nanjing University, active JP 2025 patent) proposes that siRNA/shRNA/miRNA-carrying plasmids enrich in host organ tissues and spontaneously form exosome complexes. Tsinghua University's pending CN patent claims RNA motifs (sequences CUGGGAUU or CCAGCC) appended to target mRNA termini to improve exosome packaging efficiency. Exosome loading efficiency and manufacturing scalability remain unresolved.
🔬 Preclinical — Active Patent LandscapeCNS-Specific Platforms (Intrathecal, Neuronal-Targeted)
Translate Bio's active JP patent (2024) claims intrathecal administration of liposome-encapsulated mRNA to neurons, specifically for SMA, noting the distinct lipid composition of neuronal membranes as a key barrier. Cholera toxin B subunit (CTB), binding GM1 ganglioside receptors on primary sensory neurons, delivers encapsulated dsRNA to neuronal cells with reduced toxicity versus lipid-mediated approaches.
🧪 IND-Enabling / Early ClinicalPulmonary Delivery (Inhaled RNA, Mucosal Administration)
Chitosan-based nanocapsules co-formulated with hyaluronic acid and microencapsulated in mannitol microspheres via spray-drying achieved deep lung penetration and alveolar cell transfection in vivo. LNA-modified ASOs and 2′-O-methyl siRNA are identified as candidates for inhaled lung delivery. Inhaled siRNA has reached clinical trials; inhaled miRNA and mRNA remain preclinical. Mucosal delivery circumvents serum nuclease degradation and renal clearance.
🏥 Inhaled siRNA: Clinical TrialsKey Targets Driving Tissue-Selective RNA Therapeutic Development
Myostatin (MSTN) is targeted by DCA-siRNA conjugates for systemic muscle and cardiac delivery. The continuous endothelium of muscle tissue is identified as the principal barrier to systemic oligonucleotide access. At 100 mg/kg, DCA-siRNA achieved no cytokine induction—a critical safety signal for muscle-wasting and cardiomyopathy indications. According to NIH-supported research frameworks, myostatin inhibition represents a validated therapeutic axis for muscular dystrophies.
miRNA-21 is a broadly expressed miRNA implicated in cardiac fibrosis and other pathologies. A TfR1-targeted PNA-peptide antagomir from MIT (2023) demonstrated inhibition in cardiomyocytes and in vivo across heart, liver, kidney, lung, and spleen, with demonstrated tolerability in animal models. miR-503 is delivered to endothelial cells using PAMAM dendrimer-coated carbon nanotubes, demonstrating reduced toxicity over uncoated CNTs and functional regulation of angiogenic target genes.
RelA (NF-κB subunit) is targeted by siRNA via a combined DOTAP/MC3 LNP formulation with VCAM-1 antibody coupling for active targeting to inflamed vascular endothelium. Long noncoding RNAs and circRNAs are emerging cardiac therapeutic targets studied in large-animal models including pig, rabbit, dog, and nonhuman primate. The WHO recognizes cardiovascular disease as the leading global cause of mortality, underscoring the translational urgency of these targets. PatSnap's life sciences intelligence tracks these emerging target spaces continuously.
SMN protein-encoding mRNA (CNS/SMA) is the therapeutic payload in Translate Bio's intrathecal delivery patent. Mitochondrial Complex I (via cytomegalovirus β2.7 RNA) is targeted by a National University of Singapore patent claiming an RNA subdomain as a mitochondrial delivery construct for recombinant nucleic acids—an emerging organelle-level targeting strategy.
RNA Delivery Efficacy & Platform Data Visualised
Key quantitative findings from patent and literature records, surfaced via PatSnap Eureka's innovation intelligence engine.
DCA-siRNA Myostatin Silencing Efficacy by Tissue
Docosanoic acid-conjugated siRNA achieves markedly higher myostatin silencing in cardiac muscle (~80%) than skeletal muscle (~55%), with a ~50% muscle volume increase within one week (UMass Medical School, 2021).
RNA Delivery Platform Maturity by Tissue Target
LNPs dominate clinically approved applications (liver siRNA, intramuscular mRNA vaccines). Inhaled siRNA has reached clinical trials; CNS intrathecal and muscle DCA-siRNA conjugates remain preclinical to IND-enabling stage.
Key Institutions & Commercial Entities in the RNA Delivery Patent Landscape
Innovation is distributed across academic institutions and commercial biotech. Patents signal commercial IP development; literature reflects foundational science. Tracked via PatSnap's global patent database.
Track RNA Delivery IP in Real Time
PatSnap Eureka monitors patent filings, status changes, and competitive moves across all tissue-targeted nucleic acid platforms.
Convergent Multi-Modal Delivery Strategies
Retrieved results signal five convergent combination approaches that go beyond single-platform delivery, relevant to materials and formulation innovators and cardiac/CNS therapeutic developers.
Aptamer + Nanocarrier Hybrid Targeting
Muscle-specific RNA aptamers conjugated to PEI nanoparticles enable both encapsulation (via coaxial electrospraying) and cell-specific tropism. This aptamer-functionalized nanocarrier approach is applicable across tissue types where cell-surface receptor targets exist (IDIVAL Spain, 2022).
Ultrasound-Triggered + Tissue-Responsive mRNA
Combining ultrasound-targeted microbubble destruction (UTMD) with IRES-modified mRNA carrying miRNA recognition sites creates a dual-layer tissue selectivity system—physical targeting by ultrasound plus post-delivery translational gating by endogenous tissue miRNA profiles. Particularly relevant for cardiac and solid tumor targets (Fourth Military Medical University, 2020).
From Preclinical to Clinic: RNA Delivery Translation Milestones
FDA-Approved RNA Drugs as Anchors: Multiple retrieved papers reference the 2018 FDA approval of patisiran (Onpattro®), an LNP-siRNA for hereditary transthyretin amyloidosis, and the 2021 emergency authorization of COVID-19 mRNA vaccines (Pfizer-BioNTech/Moderna) as evidence of NP-RNA platform translatability. These approvals are tracked by the FDA and represent the foundational clinical precedent for extrahepatic targeting development.
Intramuscular mRNA (Clinically Realized): Intramuscular injection of LNP-mRNA is the basis of COVID-19 mRNA vaccines currently in clinical use—the earliest and largest clinical dataset for nucleic acid muscle targeting, noted in the NCI review as the historical precedent.
Inhaled siRNA in Clinical Trials: Retrieved literature states that inhaled siRNA formulations have entered clinical trials for pulmonary diseases, though specific trial data are not detailed in the retrieved records. The EPO's patent landscape for inhaled oligonucleotides reflects growing commercial interest in this route. PatSnap customers in respiratory biotech use Eureka to monitor this competitive space.
Cardiac Noncoding RNA in Large-Animal Models: Studies in pigs, rabbits, dogs, and nonhuman primates using antisense strategies and noncoding RNA modulation are described, bridging preclinical-to-clinical translation for cardiovascular indications (Hannover Medical School, 2020).
No clinical outcomes data for muscle-specific DCA-siRNA, CNS-targeted polymer nanoparticles, chitosan/HA pulmonary systems, or exosome-based RNA delivery systems are present in retrieved records. These are assessed as preclinical.
Tissue-Specific RNA Delivery — key questions answered
Lipid nanoparticles (LNPs) are the most clinically advanced platform. Patisiran (Onpattro®) received FDA approval in 2018 for LNP-siRNA delivery, and COVID-19 mRNA vaccines (Pfizer-BioNTech/Moderna) established intramuscular LNP-mRNA as the largest clinical dataset for nucleic acid muscle targeting. Extrahepatic tissue targeting via LNPs remains predominantly preclinical.
DCA conjugation of siRNAs drives systemic delivery to both skeletal and cardiac muscle with approximately 5% injected dose efficiency, sustained silencing greater than one month, and no cytokine induction at 100 mg/kg. Targeting myostatin, DCA-siRNA achieved approximately 55% silencing in skeletal muscle and approximately 80% silencing in cardiac muscle, translating to a approximately 50% increase in muscle volume within one week.
The distinct lipid composition of neuronal membranes is identified as a key barrier necessitating optimized formulation for CNS delivery. Intrathecal administration of liposome-encapsulated mRNA is one approach, as claimed in Translate Bio's active JP patent for SMA treatment. Cholera toxin B subunit (CTB), which binds GM1 ganglioside receptors on primary sensory neurons, has also been used to deliver encapsulated dsRNA to neuronal cells with reduced toxicity.
Locked nucleic acid (LNA)-modified ASOs with phosphodiester or phosphorothioate backbones, and 2′-O-methyl-modified siRNA, are identified as candidates for lung delivery with characterized biodistribution. Inhaled siRNA formulations have entered clinical trials for pulmonary diseases. Inhaled miRNA and mRNA remain preclinical. Chitosan-based nanocapsules co-formulated with hyaluronic acid and microencapsulated in mannitol microspheres via spray-drying achieved deep lung penetration and alveolar cell transfection in vivo.
Endosomal escape via pH-sensitive ionizable lipid structural transitions is mechanistically highlighted as the key bottleneck for LNP efficacy at all tissue sites. Non-hepatic LNP targeting for cardiovascular, neurological, and infectious indications is framed as the major next-generation challenge, as liver remains the default accumulation organ following intravenous administration.
Several convergent multi-modal strategies are emerging: aptamer-functionalized nanocarriers (muscle-specific RNA aptamers conjugated to PEI nanoparticles), ultrasound-triggered delivery combined with IRES-modified mRNA carrying miRNA recognition sites for dual-layer tissue selectivity, plasmid-driven endogenous exosome production for organ-targeted delivery without nanoparticle formulation, phase-transition microneedles for cardiac gene therapy, and cation-free mRNA delivery via PEGylation through complementary RNA oligonucleotide hybridization achieving 15-fold nuclease stability improvement.
Still have questions? Let PatSnap Eureka answer them with patent and literature intelligence.
Ask Eureka AI About RNA DeliveryAccelerate Your Tissue-Targeted RNA Delivery Research
Join 18,000+ innovators already using PatSnap Eureka to surface RNA delivery patents, map competitive landscapes, and identify white space across muscle, cardiac, CNS, and lung targets.
References
- Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles — University of Massachusetts Medical School (2021)
- Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure — Charité-Universitätsmedizin Berlin (2010)
- CNS Delivery of mRNA and Methods of Use — Translate Bio, Inc. (2024, JP Patent)
- Oligonucleotide Delivery to the Lung: Waiting to Inhale — Interdisciplinary Nanoscience Center iNANO / Aarhus University (2012)
- Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles — Tel Aviv University (2021)
- The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery — NCI/Frederick National Laboratory (2022)
- Lipid nanoparticles for mRNA delivery — MIT/Koch Institute (2021)
- Coaxial Synthesis of PEI-Based Nanocarriers of Encapsulated RNA-Therapeutics to Specifically Target Muscle Cells — Health Research Institute Valdecilla (IDIVAL), Spain (2022)
- Anionic Complex with Efficient Expression and Good Safety Profile for mRNA Delivery — Nagasaki University Hospital (2021)
- Formulation for administration of RNA — TRON-Translationale Onkologie / Johannes Gutenberg-Universität Mainz (2021, EP Patent)
- A transferrin receptor 1-targeted PNA-peptide conjugate inhibits microRNA-21 expression in cardiac and other mouse tissues — MIT (2023)
- Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver — Ewha Womans University (2021)
- RNA Plasmid Delivery Systems and Their Uses — Nanjing University (2025, JP Patent)
- Ultrasound Assisted Exosomal Delivery of Tissue Responsive mRNA for Enhanced Efficacy and Minimized Off-Target Effects — Fourth Military Medical University (2020)
- RNA Molecules and Their Application in Improving the Efficiency of Exosome-Encapsulated mRNA — Tsinghua University (2023, CN Patent)
- Cell-specific and targeted delivery of RNA moieties — University of California, San Francisco (2020)
- Inhaled RNA Therapy: From Promise to Reality — University of Hong Kong (2020)
- Microencapsulated Chitosan-Based Nanocapsules: A New Platform for Pulmonary Gene Delivery — University of Santiago de Compostela (2021)
- Mucosal Delivery of RNAi Therapeutics — Aarhus University (2012)
- Pulmonary Delivery for miRs: Present and Future Potential — University of Louisiana at Monroe (2023)
- Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease — Hannover Medical School (2020)
- Clinical progress of nanomedicine-based RNA therapies — University of Southern California (2022)
- Micrornas for cardiac regeneration through induction of cardiac myocyte proliferation — ICGEB (2018, PL Patent)
- Regulation of angiogenesis through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon nanotubes — INFN-Laboratori Nazionali di Frascati (2016)
- Development of a Combined Lipid-Based Nanoparticle Formulation for Enhanced siRNA Delivery to Vascular Endothelial Cells — Leiden University (2022)
- Mitochondrial delivery of recombinant nucleic acids — National University of Singapore (2018, SG Patent)
- Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease — Shanghai Jiao Tong University (2020)
- U.S. Food and Drug Administration (FDA) — Regulatory approvals for RNA therapeutics including patisiran/Onpattro® and COVID-19 mRNA vaccines
- National Institutes of Health (NIH) — Myostatin research and neuromuscular disease therapeutic frameworks
- World Health Organization (WHO) — Cardiovascular disease global burden data
- European Patent Office (EPO) — Patent landscape for inhaled oligonucleotide therapeutics
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.